Physician profile
Eric Dessner
NPI 1861686545
$1,188.49
in general payments reported to CMS, 2019-2025
12 companies · $370 in 2025
The $370 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $158 · 2020: $63.14 · 2021: $37.18 · 2022: $73.49 · 2023: $168 · 2024: $319 · 2025: $370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $857.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $857.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $445.78 | 2022-2025 | Argos, Rocklatan, Clareon |
| Amgen INC. | $178.20 | 2024 | Tepezza |
| Mallinckrodt Enterprises LLC | $140.03 | 2019 | |
| Lilly USA, LLC | $122.95 | 2024 | Mounjaro |
| Horizon Therapeutics Plc | $75.97 | 2023 | Tepezza |
| Aerie Pharmaceuticals, INC. | $59.03 | 2019-2021 | |
| Genentech USA, INC. | $49.53 | 2022 | |
| Sun Pharmaceutical Industries INC. | $49.16 | 2020-2023 | Cequa |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Harrow Eye, LLC | $18.13 | 2024 | Vevye |
| Novartis Pharmaceuticals Corporation | $16.35 | 2021 | |
| Bausch & Lomb Americas INC. | $13.96 | 2025 | Miebo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Dessner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.